Program Schedule

Wednesday 23 January
09:30-13.00 HPCUS-AYUSH Joint Committee meeting (To be attended by the concerned people only)
16.30 Press Conference
17.00 Photo Session
Thursday 24 January
09.00 Setting the scene:
Advancing International Collaboration
  • Strategic perspectives
  • Possible scenarios
Regulators’ and Industry’s perspectives

In Chair:
S. Venkatesh (India)
Thomas Breitkreuz (Germany)
Christiaan Mol (Belgium)
Frédéric Ducher (France)
Raj K. Manchanda (India)
Why do we need international collaboration?
What kind of lessons have been learnt to date?
What kind of opportunities can be generated?
What are obstacles?
What collaboration scenarios can be distinguished?
How to deal with differences in ‘maturity’ of homeopathic regulatory tradition?
Bilateral or multinational?
10.10 Bilateral collaboration: The example of Russia and India Vadim Merkulov (Russia)
Anil Khurana (India)
What is the current regulatory status quo in Russia
What is the position with regard to bilateral collaboration between Russia and India?
10.40 TEA / COFFEE
11.10 Regulatory status: Country updates
Countries with a homeopathic tradition
Neil Gower (South Africa)
Sandra Chico (Argentina)
Diadelis Remirez Figueredo (Cuba)
Brief country updates Perspectives on collaboration are clarified
Countries with an emerging homeopathic tradition: Ahmed Mohamed Hussein Babiker (Qatar)
Ivan Kosalec (Croatia)
Monica Yeoh Siu Cheng (Malaysia)
Ronko Itamura (Japan)
Aaron To/ Yvonne Fok (China/ Hongkong)
Chandani Herath (Sri Lanka)
12.40 Pharmaceutical quality / availability

Safeguarding the quality of homeopathic medicines in Europe
Catherine Lang (France)
(video link)

History and role of EDQM is explained
Evolution of collaboration within Europe is explained
Lessons learnt are shared
13.00-14.00 LUNCH
14.00 Advancing pharmaceutical quality standards; towards a tailored approach? Experiences in Europe
Safeguarding the availability of homeopathic stocks: The role of the Remedy Bank

In chair:
Mr. MPS Bakshi (India)
Hélène Renoux (France)
Christiaan Mol (Belgium)

Jack Hendrickx (Belgium)
How to tailor safety and quality standards & controls to homeopathic medicines as 'process defined complex medicinal substances'
What are threats to the availability of homeopathic stocks? Current status quo is explained
Role of the Remedy Bank in addressing current challenges is explained
14.40 Integrating Traditional and Integrated Medicine systems in primary healthcare and public health: The example of Brazil

The role of National and Regional collaboration
Optimizing collaboration with the regulators

In chair:
Geethakrishnan G. Pillai, WHO (Switzerland)
Iracema Benvenides (Brazil)
Joao Paulo Silvério Perfeito (Brazil)
How can homeopathy and other TCIM disciplines be integrated into the healthcare system
What is the appropriate regulatory framework for integrated healthcare systems
What lessons can be learnt from experiences in Brazil, as a ‘Best Practice’ example?
15.20 TEA / COFFEE
15.50 Traditional, Complementary and Integrated Medicine (TCIM) systems: global advances in public health and regulation

In chair:
Dr. S.S. Savrikar (India)
Geethakrishnan G. Pillai, WHO (Switzerland)
Thomas Breitkreuz (Germany)
What is the role of the WHO and other Global collaboration platforms?
How to optimally link the regulation of TCIM medicinal products to the regulation of TCIM systems as a whole?
What is on the horizon for TCIM systems, with particular reference to homeopathy as a globally established TCIM modality and global healthcare challenges of the 21st century
Round table discussion on advancing collaboration between BRICS Countries
Vadim Merkulov (Russia)
Joao Paulo Silvério Perfeito (Brazil)
Neil Gower (South Africa)
Anil Khurana (India)
What are the specific opportunities offered by BRICS?
What are the priorities for regulatory collaboration?
How can regulatory collaboration be taken forward concretely?
Advancing collaboration among other countries: SAARC, EURASIA, EUROPE, LATIN AMERICA, USA
All What are priorities and opportunities for international collaboration in the regulation of HMP´s?
Can we identify best practices / models on a bi-national, regional, cross-cultural and global level?
Friday 25 January
09.00 Harmonization or ‘convergence’ on regulatory standards; Regulators' and Industry perspectives

In chair:
Joao Paulo Silvério Perfeito (Brazil)
Christiane Kirchner (Germany)
Gunther Herr (Germany)
What is the current status quo globally?

Is ‘convergence’ on standards sufficient? If so, what are the core/minimum requirements
What are legal perspectives?
How can coherence between standards be achieved as illustrated by a comparison between the European and Eurasian Economic Union laws
10.00 New homeopathic drug approval: Perspectives on setting appropriate requirements for provings and clinical data

In chair:
J.D. Daryani (India)
L.K. Nanda (India)
Todd Hoover (USA)
Robbert van Haselen (UK)
Rajesh Shah (India)
What is the role of provings in underpinning the ‘homeopathic nature’ of the medicine?
What are reasonable clinical effectiveness requirements for new homeopathic medicines?
10.30 Challenges faced by the homoeopathic industry

In chair:
K.S. Sethi (India)
GVR Joseph (India)
Ashish Kumar (India)
Mudita Arora (India)
S. M. Nurul Hoque (Bangladesh)
Nishant Jain (India)
How is the Indian regulatory system perceived?
What are perceived problems with regard to exporting Indian homeopathic medicines?
How can the Indian Industry connect internationally?
11.00 TEA / COFFEE
Theme 1 Ensuring the quality and safety of products for patients and consumers; what are appropriate standards for homeopathy?

In chair:
Jayesh Bellare, (India)
Arvind Kothe (India)
Eric Foxman (USA)
K.C. Reddy (India)
S.R. Chinta (India)
How to establish realistic requirements that provide adequate assurance of quality and safety while avoiding unreasonable or illogical demands upon industry.
Theme 2 Ensuring the quality and safety of products made from biological substances

In chair:
Raj K. Manchanda (India)
S.P. Shani (India
Shailendra Saxena (India)
Sukhbir Kaur (India)
Rajesh Shah (India)
Jack Hendrix (Belgium)
Ilse Muchitsch (Austria)
Diadelis Remirez Figueredo (Cuba)
Ivan Kosalec (Croatia)
Quality and safety parameters for nosodes and sarcodes
Further clarification of status with regard to nosodes and sarcodes
What are the challenges? Is knowledge transfer/exchange possible between countries
Theme 3 Obtaining clinical data on new and existing homeopathic medicines

In chair:
Todd Hoover (USA)
Robbert van Haselen (UK)
Anil Khurana (India)
Theodoros Lilas (Greece
How can the homeopathic community work together to obtain clinical effectiveness on new as well as existing medicines What is the role of homeopathic software platforms and Information technology in facilitating the collection of clinical data
Theme 4 Regulatory challenges with regard to the use of Homoeopathy in Veterinary Medicine

In chair:
Edward de Beukelaer (UK)
Ramankutty P. (India)
Petra Weiermayer (Austria)
Shivang Swaminarayan (India)
Surjeet Singh Makkar (India)
P.K. Naveen (India)
K.V. Athman (India)
Regulatory framework for veterinary medicine in different countries is discussed and compared
Potential for international collaboration is explored
Recommendations for India, and other countries
13.00 LUNCH
Feedback on the group discussion
Group Coordinators Main outcomes of the group discussions are fed back to plenum
Comparing the major homeopathic pharmacopoeias:
Short presentations on pharmacopoeias, followed by discussion

In chair:
K.C. Reddy (India)
Anil Khurana (India)
Europe (Austria): Ilse Muchitsch
USA: Eric Foxman
Russia: Vadim Merkulov
Brazil: Joao Paulo Silvério Perfeito
India: GVR Joseph
How far apart are the pharmacopoeias?
Is further international exchange of information needed and feasible?
How can more international convergence be achieved?
Towards a regulatory framework that optimally addresses homeopathy as a 'whole systems medical approach' using 'complex medicinal substances'?

The Future of homeopathic regulation
Perspectives by selected attendees followed by plenary discussion Can/should regulatory frameworks evolve further to recognize the specific characteristics of homeopathy as a therapeutic system?
Can lessons be learnt from other 'whole system medical approaches' that use complex substances such as Ayurveda and Anthroposophical Medicine?

How to advance collaboration; concrete steps
Does negative media coverage affect regulators / regulation? If so, how can we inform the regulators and present a balanced picture in the media?
What is on the horizon?
16.40-17.00 FORUM CLOSURE Summing up; feedback on Forum; next steps